ProCE Banner Series

Transforming Immunotherapy in NSCLC: Best Practices, Clear Communication, and Shared Decision-making

Engage with expert faculty as they provide an in-depth review of immunotherapy across the spectrum of non-small-cell lung cancer, including case discussions, clinical considerations, and audience question and answer sessions.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with NSCLC.

All Events

Transforming Immunotherapy in NSCLC: Best Practices, Clear Communication, and Shared Decision-making

Upcoming Events

July

09

2024

5:00 PM - 7:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

ProCE Banner Faculty
Kelly E.H. Goodwin, NP

Nurse Practitioner, Center for Thoracic Oncology 
Ambulatory Oncology APP Co-Director
Director, Oncology APP Professional Development
Infusion Service Line APP Director
Massachusetts General Hospital
Boston, Massachusetts

ProCE Banner Faculty
Sam Vafadar, DHSc, PA-C

Physician Associate
Thoracic Medical Oncology
Moffitt Cancer Center & Research Institute
Tampa, Florida

Topics

Lung Cancer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with NSCLC.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the rationale for neoadjuvant immunotherapy in early-stage NSCLC and considerations that can influence subsequent management of patients
  • Formulate personalized therapeutic strategies for neoadjuvant and adjuvant immunotherapy in patients with NSCLC, based on expert recommendations, current indications, and available efficacy and safety evidence
  • Apply clinical trial evidence, expert guidance, patient preferences, and predictive biomarkers to create ICI-based treatment plans for patients with advanced or metastatic NSCLC
  • Implement evidence-based strategies to monitor and manage irAEs associated with immunotherapy, including patient education on toxicities and strategies to address barriers to optimal care

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by educational grant from Bristol-Myers Squibb.